Pacific Biosciences (PACB) TD Cowen 46th Annual Health Care Conference summary

Business strategy and market positioning

• Developed a comprehensive end-to-end workflow, enabling entry into clinical markets, especially whole genome sequencing for rare diseases.

• SPARQ-Nx chemistry launching in 2026 offers higher throughput, improved accuracy, and significant cost reductions through reusable SMRT Cells.

• Competitive advantage lies in true single-molecule long-read sequencing, enabling detection of structural and epigenetic variations not possible with short-read competitors.

• Industry is experiencing commoditization in short-read sequencing, while long-read players maintain differentiation and avoid price wars.

• Positioned for global growth, with Europe and China as key markets and clinical segment as the fastest-growing revenue driver.

Financial performance and guidance

• U.S. academic market faced significant funding challenges, resulting in a $30 million revenue gap, but overall growth was maintained through strong consumables sales and new product launches.

• Clinical consumables shipments grew nearly 55% year-over-year, with clinical revenue now in the teens as a percentage of total revenue and expected to accelerate further.

• Gross margins improved by 700 basis points in 2025, with guidance for an additional 100–400 basis points improvement in 2026.

• Utilization of Revio instruments is expected to rise from the low 20% range to potentially 26–28% as project sizes and reuse increase.

• Balance sheet remains strong, with improved cash flows and reduced expenses supporting continued investment and growth.

Product innovation and customer adoption

• SPARQ-Nx beta program demonstrated 20–25% yield increases per run and consistent data quality, with full commercialization expected by early summer 2026.

• Pricing for whole genome sequencing is now highly competitive, with costs dropping below $300 per genome for large projects and further reductions at higher volumes.

• Customers are increasingly adopting multi-instrument setups for redundancy and scaling, especially in clinical labs.

• Key clinical applications include rare disease whole genome sequencing, carrier screening with customizable assays, newborn screening, and emerging interest in germline-driven oncology.

• Health economic studies and clinical evidence generation are top priorities to drive adoption and demonstrate cost-effectiveness.